NEW HAVEN, Conn., March 20 /PRNewswire-FirstCall/ -- Achillion
Pharmaceuticals, Inc., (Nasdaq: ACHN) a leader in the discovery and
development of small molecule drugs to combat the most challenging
infectious diseases, today announced that Michael D. Kishbauch, Chief
Executive Officer of Achillion, will present a corporate overview and
update on the Company's clinical programs in HIV, HCV and serious bacterial
infections at the 2007 Future Leaders in the Biotech Industry Conference,
hosted by BioCentury and Thomson Financial. The Company presentation will
take place on Thursday, March 29, 2007 from 2:00-2:25pm.
To access the live audio broadcast and the subsequent archived audio
recording of the Company presentation, please log onto the Company's
website http://www.achillion.com under the "Investors" section. The audio
recording will be archived there for 30 days following the live
presentation. Please connect to Achillion's website several minutes prior
to the start of the presentation to ensure adequate time for any software
download that may be necessary.
About Achillion
Achillion is a biopharmaceutical company focused on the discovery,
development and commercialization of innovative treatments for infectious
diseases. Achillion is currently developing treatments for HIV infection,
chronic hepatitis C infection and serious hospital-based bacterial
infections. For more information on Achillion Pharmaceuticals, please visit
the company's web site at http://www.achillion.com or call Achillion at
1-203-624-7000. ACHN-G
Contact: Media:
Mary Kay Fenton Kari Watson
Achillion Pharmaceuticals, Inc. MacDougall Biomedical Communications
Tel. (203) 624-7000 Tel. (508) 647-0209
mfenton@achillion.com kwatson@macbiocom.com
SOURCE Achillion Pharmaceuticals, Inc.
 back to top
Related links:
http://www.achillion.com
CONTACT:
Mary Kay Fenton of Achillion Pharmaceuticals,
Inc., +1-203-624-7000, mfenton@achillion.com; or Kari Watson of
MacDougall Biomedical Communications, +1-508-647-0209,
kwatson@macbiocom.com
|
